Literature DB >> 21196183

RAGE and cardiovascular disease.

Sungha Park1, Se-Jung Yoon, Hyun-Jin Tae, Chi Young Shim.   

Abstract

RAGE is pattern recognizing receptors for diverse endogenous ligands. RAGE activation by RAGE ligands is known to be associated with reactive oxygen species generation, activation of NF kappa B, as well as recruitment of proinflammatory cells. Activated endothelial cells, vascular smooth muscle cells in atherosclerotic plaques and activated inflammatory cells all have increased expression of RAGE, which with its interaction with RAGE ligands increases the secretion of proinflammatory cytokines and cell adhesion molecules. Furthermore, RAGE may have a significant role in leukocyte recruitment into the intima of the atherosclerosis. Initial insults resulting in endothelial dysfunction will result in leukocyte infiltration, oxidative stress and vascular inflammation that is amplified by RAGE activation. RAGE and its interaction with RAGE ligands may be important for initializing and maintaining the pathological processes that result in various entities of cardiovascular disease. Soluble RAGE competitively inhibits the binding of RAGE ligands to RAGE and attenuates the development of atherosclerosis in vivo. Thus RAGE may be a promising target for treatment of cardiovascular disease in the future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21196183     DOI: 10.2741/3700

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  25 in total

1.  Downregulation of high mobility group protein box-1 resensitizes ovarian cancer cells to carboplatin.

Authors:  Wen Shu
Journal:  Oncol Lett       Date:  2018-07-30       Impact factor: 2.967

2.  sRAGE attenuates angiotensin II-induced cardiomyocyte hypertrophy by inhibiting RAGE-NFκB-NLRP3 activation.

Authors:  Soyeon Lim; Myung Eun Lee; Jisu Jeong; Jiye Lee; Soyoung Cho; Miran Seo; Sungha Park
Journal:  Inflamm Res       Date:  2018-05-23       Impact factor: 4.575

3.  RAGE gene polymorphism and environmental factor in the risk of oral cancer.

Authors:  S Su; M Chien; C Lin; M Chen; S Yang
Journal:  J Dent Res       Date:  2015-01-12       Impact factor: 6.116

Review 4.  Methylglyoxal and Its Adducts: Induction, Repair, and Association with Disease.

Authors:  Seigmund Wai Tsuen Lai; Edwin De Jesus Lopez Gonzalez; Tala Zoukari; Priscilla Ki; Sarah C Shuck
Journal:  Chem Res Toxicol       Date:  2022-10-05       Impact factor: 3.973

5.  An imbalance between RAGE/MR/HMGB1 and ATP1α3 is associated with inflammatory changes in rat brain harboring cerebral aneurysms prone to rupture.

Authors:  Eiji Shikata; Takeshi Miyamoto; Tadashi Yamaguchi; Izumi Yamaguchi; Hiroshi Kagusa; Daiki Gotoh; Kenji Shimada; Yoshiteru Tada; Kenji Yagi; Keiko T Kitazato; Yasuhisa Kanematsu; Yasushi Takagi
Journal:  J Neuroinflammation       Date:  2022-06-20       Impact factor: 9.587

6.  GeneOptimizer program-assisted cDNA reengineering enhances sRAGE autologous expression in Chinese hamster ovary cells.

Authors:  Wen Wei; Ji Min Kim; Danny Medina; Edward G Lakatta; Li Lin
Journal:  Protein Expr Purif       Date:  2013-12-25       Impact factor: 1.650

7.  Unique vascular protective properties of natural products: supplements or future main-line drugs with significant anti-atherosclerotic potential?

Authors:  Mark Slevin; Nessar Ahmed; Qiuyu Wang; Garry McDowell; Lina Badimon
Journal:  Vasc Cell       Date:  2012-04-30

8.  Relationship between high-mobility group box 1 overexpression in ovarian cancer tissue and serum: a meta-analysis.

Authors:  Haipeng Wang; Zengjun Li; Yanlai Sun; Zhongfa Xu; Jianjun Han; Bao Song; Wentao Song; Chen Qin; Lei Yin
Journal:  Onco Targets Ther       Date:  2015-11-27       Impact factor: 4.147

9.  Advanced glycation end products induce human corneal epithelial cells apoptosis through generation of reactive oxygen species and activation of JNK and p38 MAPK pathways.

Authors:  Long Shi; Xiaoming Yu; Hongling Yang; Xinyi Wu
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

10.  HMGB1: A Promising Therapeutic Target for Prostate Cancer.

Authors:  Munirathinam Gnanasekar; Ramaswamy Kalyanasundaram; Guoxing Zheng; Aoshuang Chen; Maarten C Bosland; André Kajdacsy-Balla
Journal:  Prostate Cancer       Date:  2013-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.